scholarly journals A Second‐Generation MicroRNA‐Based Assay for Diagnosing Tumor Tissue Origin

2012 ◽  
Vol 17 (6) ◽  
pp. 801-812 ◽  
Author(s):  
Eti Meiri ◽  
Wolf C. Mueller ◽  
Shai Rosenwald ◽  
Merav Zepeniuk ◽  
Elizabeth Klinke ◽  
...  
2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 10575-10575 ◽  
Author(s):  
R. T. Aharonov ◽  
S. Rosenwald ◽  
T. B. Edmonston ◽  
I. Barshack ◽  
M. Feinmesser ◽  
...  

2010 ◽  
Author(s):  
Ranit Aharonov ◽  
Ayelet Chajut ◽  
Yael Spector ◽  
Shai Rosenwald ◽  
Tina B. Edmonston ◽  
...  

2011 ◽  
Author(s):  
Shai Rosenwald ◽  
Tina Edmonston ◽  
Iris Barshack ◽  
Meora Feinmesser ◽  
Monica Huszar ◽  
...  

1992 ◽  
Vol 02 (04) ◽  
pp. 529-534 ◽  
Author(s):  
HUIYING YAO ◽  
XIANZHOU ZENG ◽  
JIYAO CHEN ◽  
WEN CHEN ◽  
HUAIXIN CAI ◽  
...  

Photodynamic therapy (PDT) is a promising approach to the local destruction of malignant tumours. This method is based on the partially selective retension in tumor tissue of the photosensitizers which have photodynamic effect. It is important for PDT to determine the photosentizer concentration in tumor and in normal tissue. We quantitatively analysed the concentration of the metallic phthalocyanines, a class of photosensitizers now recognized as “second generation” PDT drugs and studied its action in different time by PIXE technique. The paper shows also the correlation between trace elements and cancer.


2010 ◽  
Vol 23 (6) ◽  
pp. 814-823 ◽  
Author(s):  
Shai Rosenwald ◽  
Shlomit Gilad ◽  
Sima Benjamin ◽  
Danit Lebanony ◽  
Nir Dromi ◽  
...  

2020 ◽  
Vol 22 (9) ◽  
pp. 1139-1150
Author(s):  
Qing Ye ◽  
Qifeng Wang ◽  
Peng Qi ◽  
Jinying Chen ◽  
Yifeng Sun ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 11036-11036
Author(s):  
S. Rosenwald ◽  
H. Gibori ◽  
S. Gilad ◽  
L. Cohen ◽  
I. Leizerman ◽  
...  

11036 Background: Hundreds of thousands of patients are diagnosed each year with metastatic cancer. For ∼10% of these, the tumor primary site is never identified, and they are defined as Cancer of Unknown Primary (CUP). Identification of tumor tissue-of- origin has significant therapeutic implications and presents a major diagnostic challenge. In previous work we showed that by combining expression profiles of tissue-specific microRNAs with a biologically-motivated classification scheme, tumor tissue-of-origin can be identified with high accuracy. Here we describe the development of this approach into a practical diagnostic assay. Methods: We developed protocols for extraction of high-quality RNA that retain the microRNA fraction from FFPE archival tissue samples. Proprietary, highly specific qRT-PCR was used to profile microRNA expression levels in hundreds of samples. Results: A training set of nearly 400 primary and metastatic tumors samples with known primary sites, representing 25 different tumor types, was used to define a standardized diagnostics assay (miRview mets). The assay uses a qRT-PCR protocol to measure a panel of 48 microRNA biomarkers. The assay was validated on a test set of nearly 200 primary and metastatic tumors whose primary sites were blinded. The classification protocol identifies either a single, high-confidence origin or two possible low-confidence predictions. Overall, correct primary site was identified for 83% of the tumors. For 70% of the cases a single high-confidence prediction was made; these cases had a higher accuracy: 90% of the primary sites predicted with high confidence were accurately identified. Conclusions: Previous studies highlighted the tissue-specificity of microRNA expression. We developed this potential into a diagnostic assay that identifies tumor origins with high accuracy. This assay provides an important new tool for diagnosing tumor tissue origin. [Table: see text]


Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.


Sign in / Sign up

Export Citation Format

Share Document